Efeito neuroprotetor da creatina e avaliação dos parâmetros cinéticos da captação de glutamato induzidos pelo ácido glutárico no estriado de ratos

• Autor(a) principal: Magni, Danieli Valnes
• Data de Publicação: 2008
• Tipo de documento: Dissertação
• Idioma: por
• Título da fonte: Manancial - Repositório Digital da UFSM
• Texto Completo: http://repositorio.ufsm.br/handle/1/11091
• topic: Ácido glutárico; Creatina; Convulsões; Glutamato; Estriado; Sinaptossomas; Excitotoxicidade; Espécies reativas; Glutaric acid; Creatine; Seizures; Glutamate; Striatum; Synaptosomes; Excitotoxicity; Reactive species; CNPQ::CIENCIAS BIOLOGICAS::BIOQUIMICA

Glutaric acidemia type I (GA-I) is an inborn error of metabolism (EIM) biochemically characterized by the main accumulation of glutaric acid (GA) and 3- hydroxyglutaric acid (3-OH-GA), and pathologically by a characteristic striatal degeneration. Due the absence of effective therapeutic strategies for this acidemia, several studies have investigated new therapies, since that one in three children subject to current treatments show striatal degeneration. In this context, the present work aimed in the first part, to investigate the effects of acute treatment with creatine (Cr), an endogenous compound guanidine which has shown neuroprotective effects in a variety of experimental models of neurodegenerative diseases and also in organic acidemias, on the GA-induced behavioral and neurochemical changes in vivo. Our results demonstrated that acute administration of Cr prevented the GA-induced behavioral and electrographic seizures, the carbonyl protein content increased and the Na+,K+-ATPase enzyme activity reduction in rats. Moreover, the Cr also protected the GA-induced sinaptossomal L-[3H]glutamate uptake reduction in vitro. As was observed in this first part, that the GA in a low concentration (10 nM) was able to reduce the L-[3H]glutamate uptake in striatal sinaptossomas of rats, and since that responsible mechanisms for striatal degeneration observed in patients are still poorly understood, we decided to evaluate in a second step, a primary action mechanism for the neurotoxic effects this low concentration of GA, which possibly may be present at the beginning of GA-I. We find that the GA reduced the L-[3H]glutamate uptake and increased the reactive species (ER) formation in sinaptossomas the striatum of rats in all times tested. Furthermore, we observed for the first time that the GA reduced the efficacy (VMax), but not the affinity (KD) of L-[3H]glutamate uptake in striatal sinaptossomas, suggesting a non-competitive inhibition. The addition of both the L-trans-pyrrolidine-2,4-dicarboxylate (PDC), a glutamate transporters inhibitor, with the GA did not alter the inhibitory effect on the of L-[3H]glutamate uptake induced by organic acid, indicating the involvement of glutamate transporters in the GA-induced uptake reduction. Since the glutamate transporters activity can be inhibited by oxidation, we show that although the antioxidant trolox protects against GA-induced ER formation increase, it did not protect against GA-induced glutamate uptake reduction in the synaptosomes of cerebral structure studied, suggesting that ER formation may be a late event in the neurotoxicity observed in GA-I. Moreover, we can not exclude the possibility that the GA may also directly stimulate the glutamate receptors, since the GA-induced ER formation was reduced by the non-NMDA glutamate receptor antagonist, the CNQX, but not by MK-801, suggesting that these receptors contributed, at least partly, to the GA-induced oxidative stress. Also determined GA, in this low concentration, did not show oxidant activity per se. Therefore, from results in this study it was observed the protective effect of Cr administration in the deleterious actions caused by the GA. Furthermore, we show for the first time that a GA low concentration cause primary excitotoxicity, and oxidative stress in brain structure predominantly affected in this disease. Therefore, we believe that this work may help explain the genesis of GA-I, as well as the development of effective adjuvant therapeutic strategies in the treatment this acidemia.